Karyopharm Therapeutics Files 8-K on Financials
Ticker: KPTI · Form: 8-K · Filed: Feb 19, 2025 · CIK: 1503802
| Field | Detail |
|---|---|
| Company | Karyopharm Therapeutics Inc. (KPTI) |
| Form Type | 8-K |
| Filed Date | Feb 19, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, results-of-operations
Related Tickers: KPTI
TL;DR
KPTI filed an 8-K on 2/19/25 detailing financial results and condition.
AI Summary
Karyopharm Therapeutics Inc. filed an 8-K on February 19, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 85 Wells Avenue, Newton, Massachusetts.
Why It Matters
This 8-K filing provides investors with an update on Karyopharm Therapeutics' financial performance and condition, which is crucial for evaluating the company's stability and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any significant new risks or negative developments.
Key Players & Entities
- Karyopharm Therapeutics Inc. (company) — Registrant
- February 19, 2025 (date) — Date of report
- 85 Wells Avenue, Newton, Massachusetts (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Karyopharm Therapeutics Inc.'s results of operations and financial condition.
When was this 8-K report filed?
This 8-K report was filed on February 19, 2025.
What is Karyopharm Therapeutics Inc.'s principal executive office address?
Karyopharm Therapeutics Inc.'s principal executive office is located at 85 Wells Avenue, 2nd Floor, Newton, Massachusetts 02459.
What is the company's state of incorporation?
The company is incorporated in Delaware.
What is the SIC code for Karyopharm Therapeutics Inc.?
The Standard Industrial Classification (SIC) code for Karyopharm Therapeutics Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 19, 2025 regarding Karyopharm Therapeutics Inc. (KPTI).